AndroGel 1.62%

DRUG3 trials

Sponsors

Repros Therapeutics Inc., AbbVie

Conditions

HypogonadismSecondary Hypogonadism

Phase 3

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

CompletedNCT01993225

Repros Therapeutics Inc.Secondary Hypogonadism

Start: 2014-01-31End: 2014-08-31Updated: 2014-10-01

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

CompletedNCT01993212

Repros Therapeutics Inc.Secondary Hypogonadism

Start: 2014-01-31End: 2014-09-30Updated: 2014-10-01

Phase 4

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

CompletedNCT04274894

AbbVieHypogonadism

Start: 2020-05-12End: 2022-01-07Updated: 2022-12-15

Related Papers

Single‐arm study of testosterone gel replacement therapy and ambulatory blood pressure outcomes in men with hypogonadism

Andrology2024-10-09